DI LORENZO, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 358
AS - Asia 196
EU - Europa 180
AF - Africa 15
SA - Sud America 12
OC - Oceania 1
Totale 762
Nazione #
US - Stati Uniti d'America 354
SG - Singapore 78
IT - Italia 58
CN - Cina 53
NL - Olanda 41
HK - Hong Kong 38
IE - Irlanda 23
VN - Vietnam 22
FI - Finlandia 20
RU - Federazione Russa 16
CI - Costa d'Avorio 15
DE - Germania 12
BR - Brasile 10
GB - Regno Unito 3
BE - Belgio 2
CA - Canada 2
FR - Francia 2
IN - India 2
TR - Turchia 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
BZ - Belize 1
CL - Cile 1
JP - Giappone 1
LT - Lituania 1
MX - Messico 1
Totale 762
Città #
Chandler 59
Singapore 52
Amsterdam 40
Hong Kong 38
Ashburn 37
Dong Ket 22
Naples 21
Princeton 20
Santa Clara 16
Beijing 15
Boston 15
Nanjing 15
Millbury 14
Napoli 12
Wilmington 8
Washington 7
Des Moines 6
Dallas 5
Dublin 5
Tianjin 5
Aversa 3
Changsha 3
Nanchang 3
Shenyang 3
Courcelles 2
Hebei 2
Jacksonville 2
Munich 2
Norwalk 2
Ottawa 2
Seattle 2
Shanghai 2
São Paulo 2
Abidjan 1
Arujá 1
Augusta 1
Belize City 1
Boardman 1
Concordia 1
Contagem 1
Darmstadt 1
Dearborn 1
Falkenstein 1
Falls Church 1
Helsinki 1
Indiana 1
Istanbul 1
Jequié 1
Jiaxing 1
Leawood 1
Los Angeles 1
Mexico City 1
Mumbai 1
Nova Iguaçu 1
Nuremberg 1
Nürnberg 1
Orindiúva 1
Palermo 1
Pune 1
Redwood City 1
Rio de Janeiro 1
Santiago 1
Santo André 1
Sciacca 1
Simões Filho 1
Sofia 1
Taizhou 1
Turin 1
Valenzano 1
Totale 478
Nome #
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 51
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 48
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 47
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 46
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance 46
. 2009 Apr;20(4):. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. 43
Predicting pathological features at radical prostatectomy in patients with prostate cancer eligible for active surveillance by multiparametric magnetic resonance imaging 43
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 42
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review 41
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 41
Docetaxel Rechallenge in a Heavily Pretreated Patient with Castration-Resistant Prostate Cancer 40
Lack of cumulative toxicity associated with cabazitaxel use in prostate cancer 39
The emerging role of obesity, diet and lipid metabolism in prostate cancer 37
Imatinib mesylate in thymic epithelial malignancies. 36
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review 35
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). 34
Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation 34
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. 33
An adjusted indirect comparison of everolimus andsorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples 32
Tumori urologici 26
Totale 794
Categoria #
all - tutte 4.339
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.339


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017 0 0 0 0 0 0 0 0 0 5 12 0
2020/202136 0 0 0 0 6 2 0 0 1 0 4 23
2021/2022121 0 0 0 2 4 1 1 5 19 11 35 43
2022/2023175 21 6 9 2 24 19 0 14 30 40 7 3
2023/2024132 4 18 19 14 7 29 2 15 0 1 12 11
2024/2025195 20 25 0 12 25 15 66 32 0 0 0 0
Totale 794